Up to 10% of cancers have a strong hereditary component. The diagnosis of a hereditary cancer may alter treatment recommendations for the patient. However, the optimal timing and best practices for integrating genetic counseling and testing into the care of women diagnosed with cancer remains unclear. In this study, we demonstrate the potential benefits of discussing genetic testing and counseling in the context of palliative care through two cases. Incorporating referrals for genetic testing into the palliative care context is important. This provides an opportunity to perform previously missed genetic testing. It is also a chance for the patient to leave a legacy while also potentially allowing for alternate targeted treatment possibilities that may be well tolerated and provide a better quality of life for the patients themselves. The benefits of referral to palliative care by the genetics team includes assisting patients with the management of not only physical but also psychological symptoms as well as conducting advanced care planning in patients and families with hereditary mutations.
Get full access to this article
View all access options for this article.
References
1.
AnandP, KunnumakkaraAB, SundaramC, et al.: Cancer is a preventable disease that requires major lifestyle changes. Pharm Res, 2008; 25:2097–2116.
2.
L HoskinsPJ, GotliebWH: Missed therapeutic and prevention opportunities in women with BRCA-mutated epithelial ovarian cancer and their families due to low referral rates for genetic counseling and BRCA testing: A review of the literature. CA Cancer J Clin, 2017; 67:493–506.
3.
MallenAR, ConleyCC, TownsendMK, et al.: Patterns and predictors of genetic referral among ovarian cancer patients at a National Cancer Institute-Comprehensive Cancer Center. Clin Genet, 2020; 97:370–375.
4.
DearingA, TavernerN: Mainstreaming genetics in palliative care: Barriers and suggestions for clinical genetic services. J Community Genet, 2018; 9:243–256.
5.
LillieAK: Exploring cancer genetics and care of the family: An evolving challenge for palliative care. Int J Palliat Nurs, 2006; 12:70–74.
6.
MorrowA, JacobsC, BestM, et al.: Genetics in palliative oncology: A missing agenda? A review of the literature and future directions. Support Care Cancer, 2018; 26:721–730.
7.
LynchHT, SnyderCL, ShawTG, et al.: Milestones of Lynch syndrome: 1895-2015. Nat Rev Cancer, 2015; 15:181–194.
BonadonaV, BonaïtiB, OlschwangS, et al.: Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA, 2011; 305:2304–2310.
10.
LeDT, UramJN, WangH, et al.: PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med, 2015; 372:2509–2520.
11.
HampelH: Genetic counseling and cascade genetic testing in Lynch syndrome. Fam Cancer, 2016; 15:423–427.
12.
LakhaniNS, WeirJ, AllfordA, et al.: Could triaging family history of cancer during palliative care enable earlier genetic counseling intervention?. J Palliat Med, 2013; 16:1350–1355.
13.
LillieAK, CliffordC, MetcalfeA: Caring for families with a family history of cancer: Why concerns about genetic predisposition are missing from the palliative agenda. Palliat Med, 2011; 25:117–124.
14.
RoelandEJ, DulleaAD, HagmannCH, MadlenskyL: Addressing hereditary cancer risk at the end of life. J Oncol Pract, 2017; 13:e851–e856.
15.
SkirtonH, FrazierLQ, CalvinAO, CohenMZ: A legacy for the children—attitudes of older adults in the United Kingdom to genetic testing. J Clin Nurs, 2006; 15:565–573.
16.
BrierleyKL, BlouchE, CogswellW, et al.: Adverse events in cancer genetic testing: Medical, ethical, legal, and financial implications. Cancer J, 2012; 18:303–309.
17.
CulverJO, BrinkerhoffCD, ClagueJ, et al.: Variants of uncertain significance in BRCA testing: Evaluation of surgical decisions, risk perception, and cancer distress. Clin Genet, 2013; 84:464–472.
18.
O'NeillSC, RiniC, GoldsmithRE, et al.: Distress among women receiving uninformative BRCA1/2 results: 12-month outcomes. Psychooncology, 2009; 18:1088–1096.
19.
HuiD, HannonBL, ZimmermannC, BrueraE: Improving patient and caregiver outcomes in oncology: Team-based, timely, and targeted palliative care. CA Cancer J Clin, 2018; 68:356–376.
20.
MooreK, ColomboN, ScambiaG, et al.: Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med, 2018; 379:2495–2505.
21.
AshworthA: A synthetic lethal therapeutic approach: Poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol, 2008; 26:3785–3790.
22.
LillieAK, CliffordC, MetcalfeA: Caring for families with a family history of cancer: Why concerns about genetic predisposition are missing from the palliative agenda. Palliat Med, 2011; 25:117–124.
23.
DanielsMS, BurzawaJK, BrandtAC, et al.: A clinical perspective on genetic counseling and testing during end of life care for women with recurrent progressive ovarian cancer: Opportunities and challenges. Fam Cancer, 2011; 10:193–197.
24.
VadaparampilST, QuinnGP, DutilJ, et al.: A pilot study of knowledge and interest of genetic counseling and testing for hereditary breast and ovarian cancer syndrome among Puerto Rican women. J Community Genet, 2011; 2:211–221.
25.
QuillinJM, BodurthaJN, SiminoffLA, SmithTJ: Physicians' current practices and opportunities for DNA banking of dying patients with cancer. J Oncol Pract, 2011; 7:183–187.
26.
QuillinJM, BodurthaJN, SiminoffLA, SmithTJ: Exploring hereditary cancer among dying cancer patients—a cross-sectional study of hereditary risk and perceived awareness of DNA testing and banking. J Genet Couns, 2010; 19:497–525.
